This is an AI translated post.
Select Language
Summarized by durumis AI
- Daewha Pharmaceutical is actively entering the Chinese market with 'Liporaxel', an improved new drug of Paclitaxel with a global market size of 5 trillion won.
- Liporaxel can be used without a solvent or auxiliary equipment, and the Chinese Paclitaxel market is expected to grow to about 1.5 trillion won.
- Daewha Pharmaceutical has been preparing for its entry into the Chinese market for over 10 years and expects to see increased revenue next year.
Daewha Pharmaceutical
Global First Drinkable Anticancer Drug
“Liporaxel” to Advance into China
Leedeily Shin Minjun reporter
Daewha Pharmaceutical's domestic sales account for over 96% of its total sales.
It has not yet made a significant global presence.
The Chinese pharmaceutical market is dominated by generics, with over 95% of the market being generics.
Special technologies may hold promise for success in China.
The products are as follows:
Liporaxel, a drinkable anticancer drug.
Patch-type dementia medicine.
Amalian hyaluronic acid filler.
Liporaxel is a modified new drug for paclitaxel, a global market worth 5 trillion won. Paclitaxel is an anticancer drug that has been used consistently for over 30 years. Liporaxel is distinguished by its lack of need for a solvent or auxiliary equipment unlike paclitaxel.
The size of the Chinese paclitaxel market is approximately 1.5 trillion won.
It's worth exploring.
Daewha Pharmaceutical signed a 100 billion won single supply contract with Shenzhen Pharmaceutical in 2018 for Amalian. However, there is no clear indication of significant achievements,
and specific figures are not provided.
Huons is already dominating the filler market.
How much market share will Amalian be able to secure?
Daewha Pharmaceutical has invested over 10 years in the Chinese market,
and expects to see increased profits next year.
